Today, immuno-oncology company Surface Oncology announced that it has reached a clinical trial cooperation with Merck (MSD) to evaluate its development of CD39 inhibitor SRF617, in conjunction with Merck's heavyweight PD-1 inhibitor Keytruda The safety and effectiveness of tumor patients. This combination therapy will be an integral part of SRF617's first phase 1 / 1b clinical study, which will focus on the treatment of gastric cancer and cancer patients that are resistant to checkpoint inhibitors.
SRF617 is a CD39 inhibitor. CD39 is a vital enzyme in the decomposition and production of adenosine triphosphate (ATP). A large number of studies have confirmed the role of CD39 in cancer immune response. For example, in gastric cancer, the immune cells in the tumor usually express high levels of CD39. Even if anti-PD-1 antibodies are present, this may damage the overall anti-cancer immune response. The combination therapy consisting of SRF617 and Keytruda has the potential to overcome this obstacle that impedes the activation of the immune system and enhances anti-tumor immunity.
"Surface Oncology is committed to developing breakthrough therapies to improve the treatment of cancer patients. The cooperation with Merck will add importance to the clinical development of SRF617 and allow us to assess its therapeutic potential more quickly," Chief of Surface Oncology Medical Officer Dr. Robert Ross said: "We have demonstrated in preclinical studies that inhibition of CD39 leads to a substantial activation of the innate and adaptive immune system. Encouragingly, we have also found The combination enhances activation and this combined approach has the potential to overcome resistance to PD-1. "